Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, ...

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...

GLP-1 agonists work by suppressing patients’ appetites and have been approved to treat obesity and type 2 diabetes in the ...

Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease ...

In this study, adolescents with obesity prescribed a glucagon-like peptide 1 receptor agonists (GLP1R) had a lower incidence of suicidal ideation or attempts compared with matched patients not ...

Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...

Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...

Nearly a quarter-of-a-million people are expected to receive the Mounjaro jab over the next three years. NHS officials have ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

Semaglutide use was associated with a lower risk for opioid overdose than other antidiabetic medications in comorbid type 2 diabetes and OUD.

New weight-loss jabs could help boost the economy in Britain by getting people “back into work”, the Prime Minister has said.

Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications.